FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3163234560> ?p ?o ?g. }

• W3163234560 endingPage "205521732110075" @default.
• W3163234560 startingPage "205521732110075" @default.
• W3163234560 abstract "Ocrelizumab is approved for the treatment of both relapsing and progressive multiple sclerosis (MS).To examine the impact of ocrelizumab on health-related quality of life (HRQOL) in individuals with MS.Ninety-eight individuals with relapsing and 32 with progressive MS were enrolled. Participants were administered a battery of patient-reported outcome (PRO) measures at their first ocrelizumab infusion, and infusions at 6 and 12 months. PRO measures included the Medical Outcomes Study SF-36 and Neuro-QoL.At baseline, participants had low mean scores across HRQOL domains. After 12 months, increases were observed on SF-36 Role-Physical, General Health, Vitality, Role-Emotional, Mental health and Mental Component Summary. On Neuro-QoL, improvements were seen in Positive Affect, Anxiety, Emotional and Behavioral Dyscontrol and Fatigue. Several demographic and clinical characteristics were associated with HRQOL at baseline. The strongest associations were between physical HRQOL measures and measures of MS disability. Associations between the longitudinal change in HRQOL scores and baseline demographic and clinical characteristics were mild.We observed significant improvements across multiple mental HRQOL domains at 12 months in individuals treated with ocrelizumab. These findings support the use of HRQOL measures to provide a subjective measure of treatment impact that complements traditional outcomes." @default.
• W3163234560 created "2021-05-24" @default.
• W3163234560 creator A5002131368 @default.
• W3163234560 creator A5043858638 @default.
• W3163234560 creator A5055725062 @default.
• W3163234560 creator A5060471106 @default.
• W3163234560 creator A5069092257 @default.
• W3163234560 creator A5070339032 @default.
• W3163234560 creator A5070437263 @default.
• W3163234560 creator A5072308136 @default.
• W3163234560 date "2021-04-01" @default.
• W3163234560 modified "2023-09-26" @default.
• W3163234560 title "The impact of ocrelizumab on health-related quality of life in individuals with multiple sclerosis" @default.
• W3163234560 cites W155259919 @default.
• W3163234560 cites W1985265957 @default.
• W3163234560 cites W1986991730 @default.
• W3163234560 cites W2005506388 @default.
• W3163234560 cites W2037377025 @default.
• W3163234560 cites W2049209937 @default.
• W3163234560 cites W2093009907 @default.
• W3163234560 cites W2103758700 @default.
• W3163234560 cites W2104948944 @default.
• W3163234560 cites W2108752110 @default.
• W3163234560 cites W2110153986 @default.
• W3163234560 cites W2115933409 @default.
• W3163234560 cites W2122545833 @default.
• W3163234560 cites W2133329597 @default.
• W3163234560 cites W2135071718 @default.
• W3163234560 cites W2139367012 @default.
• W3163234560 cites W2142577589 @default.
• W3163234560 cites W2169098250 @default.
• W3163234560 cites W2179819431 @default.
• W3163234560 cites W2561881161 @default.
• W3163234560 cites W2565433170 @default.
• W3163234560 cites W2626858991 @default.
• W3163234560 cites W4210548604 @default.
• W3163234560 cites W4292806894 @default.
• W3163234560 cites W4297966720 @default.
• W3163234560 doi "https://doi.org/10.1177/20552173211007523" @default.
• W3163234560 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8138295" @default.
• W3163234560 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34046184" @default.
• W3163234560 hasPublicationYear "2021" @default.
• W3163234560 type Work @default.
• W3163234560 sameAs 3163234560 @default.
• W3163234560 citedByCount "4" @default.
• W3163234560 countsByYear W31632345602022 @default.
• W3163234560 countsByYear W31632345602023 @default.
• W3163234560 crossrefType "journal-article" @default.
• W3163234560 hasAuthorship W3163234560A5002131368 @default.
• W3163234560 hasAuthorship W3163234560A5043858638 @default.
• W3163234560 hasAuthorship W3163234560A5055725062 @default.
• W3163234560 hasAuthorship W3163234560A5060471106 @default.
• W3163234560 hasAuthorship W3163234560A5069092257 @default.
• W3163234560 hasAuthorship W3163234560A5070339032 @default.
• W3163234560 hasAuthorship W3163234560A5070437263 @default.
• W3163234560 hasAuthorship W3163234560A5072308136 @default.
• W3163234560 hasBestOaLocation W31632345601 @default.
• W3163234560 hasConcept C118552586 @default.
• W3163234560 hasConcept C126322002 @default.
• W3163234560 hasConcept C134362201 @default.
• W3163234560 hasConcept C15744967 @default.
• W3163234560 hasConcept C159110408 @default.
• W3163234560 hasConcept C1862650 @default.
• W3163234560 hasConcept C2776035688 @default.
• W3163234560 hasConcept C2778843634 @default.
• W3163234560 hasConcept C2779338263 @default.
• W3163234560 hasConcept C2779951463 @default.
• W3163234560 hasConcept C2780640218 @default.
• W3163234560 hasConcept C2780653079 @default.
• W3163234560 hasConcept C46312422 @default.
• W3163234560 hasConcept C558461103 @default.
• W3163234560 hasConcept C71924100 @default.
• W3163234560 hasConceptScore W3163234560C118552586 @default.
• W3163234560 hasConceptScore W3163234560C126322002 @default.
• W3163234560 hasConceptScore W3163234560C134362201 @default.
• W3163234560 hasConceptScore W3163234560C15744967 @default.
• W3163234560 hasConceptScore W3163234560C159110408 @default.
• W3163234560 hasConceptScore W3163234560C1862650 @default.
• W3163234560 hasConceptScore W3163234560C2776035688 @default.
• W3163234560 hasConceptScore W3163234560C2778843634 @default.
• W3163234560 hasConceptScore W3163234560C2779338263 @default.
• W3163234560 hasConceptScore W3163234560C2779951463 @default.
• W3163234560 hasConceptScore W3163234560C2780640218 @default.
• W3163234560 hasConceptScore W3163234560C2780653079 @default.
• W3163234560 hasConceptScore W3163234560C46312422 @default.
• W3163234560 hasConceptScore W3163234560C558461103 @default.
• W3163234560 hasConceptScore W3163234560C71924100 @default.
• W3163234560 hasFunder F4320332193 @default.
• W3163234560 hasIssue "2" @default.
• W3163234560 hasLocation W31632345601 @default.
• W3163234560 hasLocation W31632345602 @default.
• W3163234560 hasLocation W31632345603 @default.
• W3163234560 hasOpenAccess W3163234560 @default.
• W3163234560 hasPrimaryLocation W31632345601 @default.
• W3163234560 hasRelatedWork W2272446420 @default.
• W3163234560 hasRelatedWork W2583199985 @default.
• W3163234560 hasRelatedWork W2617222556 @default.
• W3163234560 hasRelatedWork W2904697613 @default.

• next